ADIPOQ, ADIPOR1, and ADIPOR2 Polymorphisms in Relation to Serum Adiponectin Levels and BMI in Black and White Women by Cohen, Sarah S. et al.
ADIPOQ, ADIPOR1, and ADIPOR2 Polymorphisms in Relation to
Serum Adiponectin Levels and Body Mass Index in Black and
White Women
Sarah S. Cohen1,2, Marilie D. Gammon1, Kari E. North1,3, Robert C. Millikan1, Ethan M.
Lange4, Scott M. Williams5, Wei Zheng6, Qiuyin Cai6, Jirong Long6, Jeffrey R. Smith7, Lisa
B. Signorello2,6, William J. Blot2,6, and Charles E. Matthews8
1Department of Epidemiology, University of North Carolina, Chapel Hill, NC
2International Epidemiology Institute, Rockville, MD
3Carolina Center for Genome Sciences, University of North Carolina, Chapel Hill, NC
4Departments of Genetics and Biostatistics, University of North Carolina, Chapel Hill, NC
5Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine,
Nashville, TN
6Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt
University School of Medicine, and Vanderbilt-Ingram Cancer Center, Nashville, TN
7Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN
8Nutritional Epidemiology Branch, National Cancer Institute, Rockville, MD
Abstract
Adiponectin is an adipose-secreted protein with influence on several physiologic pathways
including those related to insulin sensitivity, inflammation, and atherogenesis. Adiponectin levels
are highly heritable and several single nucleotide polymorphisms (SNPs) in adiponectin-related
genes (ADIPOQ, ADIPOR1, ADIPOR2) have been examined in relation to circulating
adiponectin levels and obesity phenotypes, but despite differences in adiponectin levels and
obesity prevalence by race, few studies have included black participants. Using cross-sectional
interview data and blood samples collected from 990 black and 977 white women enrolled in the
Southern Community Cohort Study from 2002 to 2006, we examined 25 SNPs in ADIPOQ, 19 in
ADIPOR1, and 27 in ADIPOR2 in relation to serum adiponectin levels and body mass index
(BMI) using race-stratified linear regression models adjusted for age and percentage African
ancestry. SNP rs17366568 in ADIPOQ was significantly associated with serum adiponectin levels
in white women only (adjusted mean adiponectin levels = 15.9 for G/G genotype, 13.7 for A/G,
and 9.3 for A/A, p=0.00036). No other SNPs were associated with adiponectin or BMI among
blacks or whites. Because adiponectin levels as well as obesity are highly heritable and vary by
race but associations with polymorphisms in the ADIPOQ, ADIPOR1, and ADIPOR2 genes have
been few in this and other studies, future work including large populations from diverse racial
groups is needed to detect additional genetic variants that influence adiponectin and BMI.
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INTRODUCTION
Adiponectin is a collagen-like protein secreted by adipose tissue and found in relatively high
concentration in serum (1). Adiponectin plays an important role in several physiological
pathways including those related to insulin action, inflammation, and atherogenesis (1, 2)
and is believed to affect the development and progression of several diseases including
cardiovascular disease, diabetes, and cancer at several sites including breast, endometrial,
and colorectal (3, 4). Adiponectin levels show a strong inverse association with adiposity (1)
and also vary by gender and race with lower levels in women compared to men (5) and in
blacks compared to whites (6).
Adiponectin is encoded by the gene ADIPOQ, located on chromosome 3q27. Two
adiponectin receptors have been identified and are encoded by the genes ADIPOR1 (located
on chromosome 1q32) and ADIPOR2 (located on chromosome 12q13). Heritability
estimates for adiponectin are high (ranging from 30% to 70%) (7, 8) indicating that the
genes encoding adiponectin and its receptors are plausible candidates for association with
serum levels of the protein. Additionally, because adiponectin is strongly associated with
body size, the adiponectin-related genes are also reasonable candidate genes for association
with obesity phenotypes. Single nucleotide polymorphisms (SNPs) in the ADIPOQ,
ADIPOR1 and ADIPOR2 genes have been examined in association with adiponectin levels
and obesity phenotypes in several studies but results have been quite inconsistent (7).
Further, virtually no studies of these genes have included black participants despite known
racial differences in the prevalence of obesity (9) and evidence showing differences in
adiponectin levels by race (6). Thus, the goal of this study was to examine polymorphisms in
ADIPOQ, ADIPOR1 and ADIPOR2 in relation to adiponectin levels and body mass index
(BMI) in a large sample of both black and white women.
METHODS AND PROCEDURES
Institutional Review Boards at Vanderbilt University, Meharry Medical College, and the
University of North Carolina at Chapel Hill approved this study.
Study population
The Southern Community Cohort Study (SCCS) is a prospective epidemiologic cohort study
designed to examine racial disparities in cancer incidence and mortality and other health
outcomes (10). Study enrollment began in 2002 in twelve southeastern states at Community
Health Centers (CHC) which are government-funded facilities providing health services
primarily to low-income individuals in medically underserved areas. As described
previously (10), participants were required to be age 40–79 years of age, English-speaking,
and not have undergone treatment for cancer within the past year. From over 47,000
participants enrolled through early 2006, a sample of 2,000 women who provided a blood
sample at study enrollment and self-reported their race as only ‘Black/African American’ or
‘White’ was selected for biomarker analyses. This included a random sample of 395 women
selected in 2005 within strata of race (black/white), BMI (18.5–24.9, 25–29.9, and 30–45),
and smoking cigarette status (current/former/never), and a second random sample of 1,605
women selected in 2006 in equal numbers across race, BMI (18.5–24.9, 25–29.9, 30–34.9,
and 35–45), and menopausal status categories (pre/post).
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Trained study interviewers conducted structured baseline interviews with participants using
a computer-assisted interview which elicited information including demographics,
anthropometrics, and several aspects of health and behavior. Height and weight at the time
of the baseline interview were self-reported by participants and used to calculate BMI as
[weight (kg)]/[height (m)2]. For the 20% of women who were patients in the CHC on the
day of the baseline interview, measured height and weight were abstracted from medical
records for validation purposes.
A convenience blood sample was collected at the time of recruitment using one EDTA-
containing plasma BD Vacutainer® tube and one serum BD Vacutainer® tube. For this
study, the median time between the last reported meal and blood collection was 6.0 hours for
blacks and 6.3 hours for whites. Fasting blood, defined as at least 8 hours since last meal,
was collected for 44% of the participants. Blood samples were shipped cold to Vanderbilt
University in Nashville, TN, where they were processed for storage at −80° C. 84% of the
blood samples were received the day after the blood draw and 98% were received within
two days. The samples were frozen for an average of 2.6 years (range 3 months to 5 years)
prior to analysis.
Adiponectin measurement
Adiponectin was measured in serum by immunoassay using the LINCOplex kit (Luminex®
xMAP™ Technology, St. Louis, MO) in the Vanderbilt Hormone Assay and Analytical
Services Core Laboratory in duplicate for each woman. The average of the two
measurements was used in all analyses. Duplicate sets of samples for five randomly selected
women as well as five repeat samples from each of two pooled samples were measured to
assess the reliability of the assay. Adiponectin was successfully measured in 1,992 of the
2,000 samples (eight samples failed due to a filter plate error or low sample volume). The
intra-assay coefficient of variation for the 1,992 samples run in duplicate was 9.4%.
Genotyping of SNPs
SNPs located in the three genes encoding adiponectin and its receptors, ADIPOQ,
ADIPOR1, and ADIPOR2, were selected for this study. The Caucasian (CEU) and West
African (YRI) populations in the International HapMap project (release 22) were the
primary data source for the selection of the SNPs (11). We identified all HapMap SNPs
within each gene including an additional 10 kb to each flank (encompassing potential
regulatory elements).. All SNPs were scored for the ability to perform well on the Illumina
GoldenGate genotyping platform using an Illumina in-house algorithm (Illumina Inc., San
Diego, CA). SNPs that failed the scoring for the Illumina assay were omitted as were those
with a minor allele frequency (MAF) < 0.05 in both CEU and YRI subjects while SNPs with
a MAF ≥ 0.05 for either CEU or YRI subjects were retained. The LDSelect algorithm was
then run separately for the CEU and YRI data using an r2 cut-off of 0.8 to partition SNPs
into LD bins for each population (12). When multiple tagging SNPs were found for a
linkage disequilibrium (LD) bin, those SNPs designated as tagging SNPs in both populations
were preferentially selected for efficiency. Among equivalent tag SNPs of a given LD bin,
one categorized as a candidate functional SNP or one previously employed on Illumina
chips was preferentially selected for assay. The total selected set of tagging SNPs efficiently
and systematically captured genetic diversity at these genes in both populations. Twenty-
five tagging SNPs were selected for the ADIPOQ gene, 19 for ADIPOR1, and 27 for
ADIPOR2.
An additional 300 SNPs were selected as ancestry informative markers (AIM) (13). AIMs
were required to pass the Illumina scoring algorithm, be at least 5 Mb from the candidate
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genes, have a MAF > 0.05 in both the CEU and YRI populations, and have an allele
frequency difference between the CEU and YRI populations > 0.6. Of the 300 selected AIM
SNPs, 292 passed the Illumina scoring algorithm and 276 were successfully genotyped.
Genomic DNA was extracted from buffy coat using QIAamp DNA kits (Qiagen, Valencia,
CA) according to manufacturers’ instructions. Genotyping took place at Vanderbilt
University. The SNPs included in this project were genotyped along with those from a larger
study of obesity in this study population to facilitate the use of the Illumina GoldenGate
genotyping platform (Illumina Inc., San Diego, CA). Blinded QC samples (N=29) and
another 171 pairs of duplicated samples were included and the consistency rate was 99.9%.
Statistical Methods
Of the 2,000 women selected for analysis, genotyping was successful for 1,990. Individuals
were assigned admixture estimates (called ancestry allelic clusters or AAC) using the 276
genotyped AIMs and STRUCTURE Version 2.2.3 software (14). Given that the participants
in this project were selected for inclusion based on self-reported race being only black or
white (and the number of Asian and Hispanic participants in the SCCS overall is very low),
the number of ancestral populations to be estimated was a priori specified to be 2. Thus two
AACs were generated for each individual: one for African ancestry and one for European
ancestry. Twenty-three women were excluded from further analysis because of
discrepancies between self-reported race and ancestry estimates derived from STRUCTURE
(6 self-reported black women with less than 20% estimated African ancestry and 17 self-
reported white women with more than 30% estimated African ancestry) leaving 1,967
women for study (N=990 black and N=977 white). For analyses with adiponectin as the
primary outcome, data from 1,959 women were analyzed after excluding eight additional
samples in which adiponectin could not be measured due to low blood sample volume or a
filter plate error.
We tested for Hardy-Weinberg equilibrium in race-stratified samples and found one SNP in
ADIPOQ (rs1648707) that showed significant deviation from Hardy-Weinberg equilibrium
in both white (p=8.6×10−16) and black (p=1.3×10−16) women. This SNP was excluded from
all further analyses.
Linkage disequilibrium (LD) was calculated and displayed between each of the genotyped
SNPs, stratified by race, using the r2 metric and Haploview software (Supplementary Figure
1).
Associations between individual SNPs and adiponectin levels were examined using race-
stratified multiple linear regression models with log-transformed adiponectin as the outcome
(adjusted mean adiponectin levels for each genotype were back-transformed for
presentation). Similar models were also constructed with BMI as the outcome variable.
SNPs that were found to have a MAF < 0.001 within a race group were omitted from further
analyses in that race group. SNPs were generally examined using a codominant inheritance
model (with 2 degrees of freedom) which was selected because there was no a priori
hypothesis about the model form for the SNP-adiponectin associations or the SNP-BMI
associations, and the use of the two degree of freedom test for the co-dominant model has
been shown have good overall performance for any of the possible underlying modes of
inheritance (15). The referent genotype was selected to be the most common race-specific
homozygous genotype. For SNPs in which less than 10 women had the rare homozygous
genotype, a dominant model was used that combined women with the rare homozygous
genotype with those with the heterozygous genotype. Each regression model included
adjustment for age at baseline SCCS interview as well as percentage of African ancestry as
estimated by STRUCTURE. Models substituting the first five principal components derived
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using EIGENSTRAT software (16) in place of the AAC derived from STRUCTURE were
also examined and found to have very similar results. SAS/STAT version 9.2 (SAS Institute,
Cary, NC) was used for all modeling.
A Bonferroni correction was applied to the a priori alpha level of 0.05 and was calculated
based on the number of individual models examined for each SNP over the three genes of
interest. p-values of 0.00096 and 0.00075 were used to determine statistical significance for
white and black women, respectively, based on the analysis of 52 and 67 SNPs.
RESULTS
Consistent with the stratified sampling design for this study, equal percentages of black and
white women were post-menopausal, and women in both race groups had a mean BMI
(BMI) of approximately 30 kg/m2 (Table 1). Income and education distributions between the
race groups were also similar. Adiponectin levels were lower in black women than in white
women (15.4 v 19.9, mg/ml, p<0.0001). There were no differences in adiponectin levels by
fasting blood status (black fasting v. non-fasting mean=14.9 v. 15.9, p=0.25; white fasting v.
non-fasting mean=20.2 v. 19.6, p=0.6).
The location and genotype frequencies of the SNPs selected for the three genes of interest
are described in Tables 2a, 2b, and 2c. Genotyping was successful for all 1,967 women for
58 (84%) of the SNPs and over 96% complete for the other 11 SNPs. More tag-SNPs were
needed to provide adequate gene coverage for the black sample compared to the white
sample.
Adjusted mean adiponectin levels by genotype are shown in Figure 1 for ADIPOQ,
ADIPOR1, and ADIPOR2 separately for black and white women. Among white women,
one SNP, rs17366568 in the ADIPOQ gene, met the Bonferroni p-value threshold for
significance. The adjusted mean adiponectin levels for rs17366568 were 15.9 for white
women with the G/G genotype, 13.7 for those with the A/G genotype, and 9.3 for those with
the A/A genotype (p=0.00036). This SNP was not in LD with any of the other genotyped
SNPs (Supplementary Figure 1). The additive genetic model was also examined for SNP
rs17366568 in ADIPOQ in white women, and this SNP was significantly associated with
adiponectin using the additive model with little difference seen compared to the co-
dominant model (additive model p-value=0.0002). BMI was added as a covariate to the
linear regression model for rs17366568 in ADIPOQ in relation to adiponectin levels, and
while BMI was found to be strongly associated with adiponectin itself, its inclusion did not
alter the association between the SNP and adiponectin levels in white women (mean
adiponectin levels for rs17366568 were 15.9 (G/G genotype), 13.6 (A/G), and 9.7 (A/A),
p=0.00011 after adjustment for BMI).
The genotype distribution for SNP rs17366568 differed significantly between the white and
black women (χ2 p-value <0.0001). For the black women, adjusted mean adiponectin levels
were 11.7 for women with the G/G genotype and 11.6 for women with the A/G or A/A
genotypes (only one black woman had the A/A genotype) and the SNP was not associated
with adiponectin levels using a dominant genetic model (p=0.92).
Interactions between SNP rs17366568 and BMI, diabetes status, and menopausal status in
white were also examined. Of these factors, only BMI was found to be a significant effect
modifier of the SNP-adiponectin association (likelihood ratio p-value < 0.0001 for
interaction). A strong positive association was seen for adiponectin levels among non-
overweight women (<25 kg/m2) (adiponectin=8.1, 19.3, and 23.7 ug/ml for A/A, A/G, and
G/G genotypes, respectively; p=0.004); this marked increase in adiponectin levels across
genotype was not as clear in the other strata of BMI (25–29.9, 30–34.9, and 35–45 kg/m2).
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However, these interaction models should be considered exploratory as the number of
individuals in some cells was very small (for example, N=3 for individuals with BMI <25
kg/m2 and genotype A/A).
Beyond SNP rs17366568 in white women, we observed no significant associations between
adiponectin levels and individual SNPs in either the black or white women. Figure 2 shows
adjusted mean BMI values by genotype for the three genes of interest. There was little
variation by BMI across genotypes in any of the SNPs and none met the Bonferroni p-value
thresholds for significance although p-values less than 0.05 were observed for five SNPs in
ADIPOR2 among the black women.
DISCUSSION
This study examined variation in three adiponectin-related genes in relation to adiponectin
levels and BMI in a large sample of black and white women. We observed a significant
association between adiponectin levels and SNP rs17366568 in ADIPOQ among white
women but this SNP was not found to be associated with adiponectin levels among black
women. Determining SNPs that affect either adiponectin levels or BMI, and ascertaining
whether these SNPs differ across racial groups, is an important step in our understanding of
the roles played by adiponectin and obesity in the complex mechanisms underlying racial
disparities for major chronic disease such as cancer, diabetes, and cardiovascular disease.
Individuals of African descent display, on average, more variation in allele frequency than
do people of European descent, indicating that the frequency of etiologically important
SNPs may differ by race. The difference in the association with adiponectin levels and SNP
rs17366568 between black and white women in this study seems at least in part due to allele
frequency differences, with a MAF (A allele) of 0.14 in the white women and only 0.015 in
the black women. This is consistent with the results of the HapMap project in which all of
the YRI samples were found to have the G/G genotype (and thus this SNP is not shown on
the LD plot for the HapMap YRI population, Supplementary Figure 2, top panel).
The statistically significant results for SNP rs17366568 in ADIPOQ in white women in
relation to adiponectin from our study were very similar to those seen in two recent genome-
wide association studies (GWAS) studies of European whites (8, 17). The A/A genotype
was relatively rare in our study (MAF=0.14 in white women) as it was in the two GWAS
(MAF=0.11 and 0.13) (8, 17). The effect size (using log-transformed adiponectin, ug/ml, as
the outcome) for an additive model was 0.20 for each addition of the G allele in the KORA
portion of the Heid study (8), which was very close to our effect estimate of 0.18 for a
similar model. The proportion of variance explained by this SNP was 1.7% in our study,
lower than the 5.3% reported for women in one GWAS (8) but close to the <2% reported in
the other GWAS (17). These similar findings are especially striking given the difference in
study design between the GWAS and our biological hypothesis-driven study. A third GWAS
conducted in white Europeans reported four SNPs in ADIPOQ to be significant associated
with circulating adiponectin, one of which was measured in our study (rs6444175) and
found not to be associated with adiponectin in whites (p=0.5), another (rs1648707) which
was in strong LD with a SNP genotyped in our study (rs182052) which was also not
associated with adiponectin in whites (p=0.1), and two not genotyped in our study (18).
In our study, we found no additional SNPs beyond rs17366568 that were associated with
adiponectin in black or white women. Adiponectin levels have been examined in relation to
variants in ADIPOQ in more than a dozen association studies of white and Asian individuals
but few specific SNPs or haplotypes have been replicated in multiple populations. Four
common ADIPOQ polymorphisms (rs2241766 (commonly called 45T→G), rs1501299
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(commonly called 276G→T), −11391G→A, and −11377C→G) were genotyped in early
candidate gene studies for association with adiponectin with inconsistent results (19–27).
Several of these studies were examined in a 2007 meta-analysis of genetic variants in
ADIPOQ in relation to adiponectin levels. Menzaghi et al. reported that two commonly
typed SNPs in ADIPOQ, rs17300539 and rs1501299, were significantly associated with
adiponectin levels in the meta-analysis of five and twelve studies, respectively (7). Neither
of these SNPs was genotyped in our study but each was in strong LD with selected tag-SNPs
that were genotyped. In the HapMAP CEU population (release 22), both rs822387 and
rs16861210 had a pairwise r2 value of 0.82 with rs17300539, but neither was found to be
significantly associated with adiponectin levels in white women in our study (p=0.2 for
rs822387 and p=0.1 for rs16861210). SNP rs6444175 in ADIPOQ had a pairwise r2 value of
0.92 in the CEU population and an r2 of 0.53 in the YRI population with rs1501299, but
rs6444175 was not significantly associated with adiponectin levels in our study (p=0.5 for
white women and p=0.6 for black women). As genotyping larger numbers of SNPs has
become easier and more cost-efficient, additional SNPs in ADIPOQ have been examined in
relation to adiponectin levels but still little consistency has been observed in association with
adiponectin across studies (5, 28–31).
LD plots for ADIPOQ for the HapMap YRI and CEU populations are shown in
Supplementary Figure 2 (top and bottom panels, respectively) and the differences in the LD
structures between the YRI and CEU populations demonstrate the importance of examining
genetic correlates of adiponectin and obesity in racially diverse populations. However, to
date, polymorphisms in ADIPOQ have been examined largely in populations that did not
include individuals of African descent. One genome-wide linkage scan which included both
89 Hispanic families and 42 black families reported heritability estimates of 71% and 64%
in Hispanics and blacks, respectively, for adiponectin, but the region of the genome where
ADIPOQ is located was identified as a major quantitative trait loci only in the Hispanic
sample (32). The HERITAGE study included 276 black participants and found two variants
in ADIPOQ that were associated with measures of body fat in blacks but not whites (33). In
a recent study from the CARDIA population, ten tagSNPs were examined and five were
found to be significantly associated with adiponectin among white participants while only
one SNP was found to be marginally significant among blacks (34). Comparisons to our
results are limited by the combination of effects across gender groups, the narrower age
range of participants (33–45 years), and the genotyping of a different set of tagSNPs in the
CARDIA study. Collectively, the body of literature examining genetic variation in
adiponectin-related genes among blacks is small, but studies to date, including ours, offer an
indication that different variants may have differing effects on circulating levels across race
groups.
Regarding BMI, several studies have reported positive associations between BMI and a
variety of ADIPOQ polymorphisms (35–38) while others have not found any significant
effects (20, 23, 27, 30, 33). No significant associations with BMI were found with SNPs in
ADIPOQ in the Menzaghi et al. 2007 meta-analysis (7). Of the SNPs in ADIPOQ examined
to date in relation to BMI, only rs182052, found to be associated with BMI in a group of
over 800 Hispanic individuals (37), was also genotyped in our study but we did not find any
association with BMI in black (p=0.95) or white women (p=0.14).
Very few studies have examined polymorphisms in ADIPOR1 and ADIPOR2 in relation to
adiponectin or BMI. No genome-wide significant associations between adiponectin levels
and SNPs in either ADIPOR1 or ADIPOR2 were found in a GWAS of Europeans (17). Loos
et al. investigated two SNPs in ADIPOR1 (rs1539355 and rs2275737) and two in ADIPOR2
(rs0773982 and rs2058112) in relation to BMI in French-Canadians and found no
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statistically significant associations (27); we also observed no association with BMI for
these four SNPs in black or white women.
High heritability estimates for both adiponectin levels and obesity as well as linkage studies
showing the adiponectin-related genes to be strongly related to these phenotypes indicate
that, while the evidence to date has been inconsistent, polymorphisms in the genes encoding
adiponectin and the two known adiponectin receptors remain promising avenues for
explaining variation in adiponectin levels as well as obesity. Conflicting results to date may
be due to a myriad of differences across studies including sample size, analysis methodology
(including the examination of single-SNPs versus haplotypes, differing approaches to
confounding, control for population stratification, and multiple comparisons), genetic
background, and possibly environmental or gene-gene influences across populations.
It remains possible that there are unknown rare variants that have a strong effect on
adiponectin levels, and few studies to date, including ours, have been powered to detect rare
variants. There may also be many as-yet unidentified common loci with small individual
effects on adiponectin levels. Additionally, genetic contribution to adiponectin variation
may be influenced by interactions between multiple loci or between loci and environmental
factors or perhaps by epigenetic factors, none of which have been carefully examined yet.
A major strength of this study was the use of participants from the SCCS which allowed for
the examination of adiponectin levels and BMI in relation to genetic variation in
adiponectin-related genes in both black and white women of similar socioeconomic status
and geographic locale. SNPs were selected to provide coverage across the genes using both
the HapMap CEU and YRI populations which resulted in similar precision in estimating
sequence variation in both the black and white participants. The large sample of black and
white women provided adequate power to detect meaningful changes in adiponectin and
BMI. Power calculations for adiponectin show that for changes in adiponectin levels greater
than 5.0 ug/mL across genotypes, SNPs with MAF greater than 0.07 were well-powered
(power ≥ 80%). For BMI, power was above 80% for all but the SNPs with the lowest MAF
(<0.06) for a change in BMI of 2.5 kg/m2 across genotypes.
Study limitations include the potential for measurement error in either of the outcome
variables of adiponectin and BMI. As is common in large population-based studies, we
measured total adiponectin rather than high-molecular weight adiponectin. Additionally, we
only measured adiponectin at one point in time; however, adiponectin levels measured one
year apart have been reported to be highly correlated and likely sufficient for large
epidemiologic studies (39). We also did not require participants to provide fasting blood
samples although we found no differences in the mean adiponectin levels by fasting status.
For BMI, we used self-reported height and weight measures to calculate BMI. While there is
evidence to indicate that women tend to over-report height while under-reporting weight
(40), BMI values calculated from self-reported height and weight in the SCCS were very
highly correlated with BMI values calculated from medical record data overall (Pearson
correlation coefficient > 0.95) as well as across strata of race and BMI, indicating that the
self-reported values are generally of high quality. A further limitation of this study is the
lack of information regarding central obesity, which may be a stronger correlate of disease
risk than BMI and has been observed to vary across race groups for a given BMI (41).
Finally, the use of a Bonferroni correction is a potential limitation as it is a conservative
approach that is unable to account for the correlation structure inherent among a group of
SNPs (42). Despite the conservative nature of the Bonferroni correction, its application did
not drastically alter the interpretation of these results. There were few SNPs that were
significantly associated with adiponectin or BMI at an alpha level of 0.05 (5 total for
adiponectin and 9 total for BMI, out of 119 total associations examined). Further, there was
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no evidence of clustering of SNPs with lower p-values in any specific regions of the genes
examined. None of these 14 SNPs are known to be functional variants nor have they been
found in previous studies to be associated with these outcomes. They may, however,
represent areas of the genes worthy of further exploration in future studies.
In this study of genetic variation in adiponectin-related genes in relation to adiponectin and
BMI among both black and white women, we demonstrated that there may be different
genetic variants that contribute to variation in adiponectin levels by race. Our observation of
an association between SNP rs17366568 in ADIPOQ and adiponectin levels in white
women was also recently reported by two GWAS of European women. To our knowledge,
our study is the first to examine these three genes in relation to adiponectin among black
women and we did not find any association with SNP rs17366568 or others in black women.
Additionally, we found no other SNPs that were associated with adiponectin levels or with
BMI in black or white women. Future discovery of additional variants that affect
adiponectin levels (and particularly rare variants that may occur only in certain race groups)
as well as detection of gene-gene and gene-environment interactions related to adiponectin
levels and BMI will require future studies with large sample sizes from multiple racial
groups.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Adjusted mean adiponectin levels (ug/ml) and associated p-values from race-stratified linear
regression models for SNPs in ADIPOQ (left panel), ADIPOR1 (center panel), and
ADIPOR2 (right panel) among 990 black women and 977 white women, Southern
Community Cohort Study, 2002–2006. The horizontal bars represent mean adiponectin
levels for each SNP by genotype with the top bar in each grouping representing the Test/
Test genotype, the middle bar representing the Test/Reference genotype, and the lower bar
representing the Reference/Reference genotype (see Tables 2a, 2b, and 2c for Test and
Reference allele listings). Two bars indicate that the rare homozygous genotype was
combined with the heterozygote genotype for analysis. p-values refer to tests for differences
in adiponectin levels across genotypes. SNP meeting the Bonferroni p-value threshold
indicated by asterisks (***).
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Adjusted mean body mass index (BMI) (kg/m2) values and associated p-values from race-
stratified linear regression models for SNPs in ADIPOQ (left panel), ADIPOR1 (center
panel), and ADIPOR2 (right panel) among 990 black women and 977 white women,
Southern Community Cohort Study, 2002–2006. The horizontal bars represent mean
adiponectin levels for each SNP by genotype with the top bar in each grouping representing
the Test/Test genotype, the middle bar representing the Test/Reference genotype, and the
lower bar representing the Reference/Reference genotype (see Tables 2a, 2b, and 2c for Test
and Reference allele listings). Two bars indicate that the rare homozygous genotype was
combined with the heterozygote genotype for analysis. p-values refer to tests for differences
in BMI across genotypes.
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Table 1
Characteristics of black and white women genotyped for ADIPOQ, ADIPOR1, and ADIPOR2 from the
Southern Community Cohort Study, 2002–2006
Black women (N=996) White women (N=994)
Mean [std] Mean [std]
Age at baseline interview (years) 50.1 [8.9] 49.9 [8.6]
Body mass index (kg/m2) 30.4 [6.4] 30.3 [6.6]
Adiponectin (ug/ml) 15.4 [13.4] 19.9 [16.1]
N (%) N (%)
Education
 <9 years 78 (7.8) 86 (8.7)
 9–11 years 243 (24.4) 221 (22.2)
 Completed high school 411 (41.3) 411 (41.4)
 More than high school 264 (26.5) 276 (27.8)
Annual Household Income
 < $15,000 621 (62.9) 597 (60.3)
 $15,000 – 24,999 233 (23.6) 199 (20.1)
 $25,000 – 49,999 116 (11.8) 130 (13.1)
 $50,000+ 17 (1.7) 64 (6.5)
 Missing 9 4
Menopausal status
 Pre 497 (49.9) 497 (50.0)
 Post 499 (50.1) 497 (50.0)
Diabetesa
 Yes 218 (21.9) 162 (16.3)
 No 778 (78.1) 832 (83.7)
a
Self-reported from the question “Has a doctor ever told you that you have had diabetes?”
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